Display Settings:

Format

Send to:

Choose Destination

    Vaccine. 2008 Aug 5;26(33):4251-5. Epub 2008 Jun 9.

    Cost effectiveness of rabies post exposure prophylaxis in the United States.

    Dhankhar P, Vaidya SA, Fishbien DB, Meltzer MI.

    Division of Emerging Infections and Surveillance Services, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, MS-D59, Atlanta, GA 30333, United States.

    There is growing concern in the United States about the excessive use of rabies post exposure prophylaxis (PEP) treatment. In this paper we have estimated the cost effectiveness of rabies PEP treatment under various scenarios of rabies transmission. When the risk of a patient getting rabies is deemed greater than 0.7%, then giving PEP will be cost saving (societal perspective). For lower risks of transmission, cost effectiveness estimates ranged from approximately $500,000 per life saved to $billions. The uncertainty caused by the wide range of cost effectiveness can only be resolved through analysis of data describing rabies transmission risk in a variety of scenarios.

    PMID: 18599167 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information

    • Rabies Vaccine (Imovax®, RabAvert®)

      Rabies is a serious disease. It is caused by a virus. Rabies is mainly a disease of animals. Humans get rabies when they are bitten by infected animals.